Hawaii Hemp Restrictions: Federal Lawsuit, State Enforcement & Industry Impact

Executive Summary

Hawaii state officials face a federal lawsuit challenging newly enforced hemp product restrictions that took effect July 1, 2026, threatening to eliminate approximately 90 percent of existing hemp retail inventory across the state. The enforcement action stems from legislation passed in 2025 that imposes stringent testing, labeling, and potency requirements on hemp-derived products containing cannabinoids like delta-8 THC, delta-10 THC, and THCA. Retailers, manufacturers, and industry advocates filed suit in U.S. District Court arguing the state regulations conflict with federal law under the 2018 Farm Bill and violate interstate commerce protections. The crackdown affects hundreds of small businesses operating hemp shops, vape stores, and CBD retailers throughout the Hawaiian islands, with operators warning of imminent closures and job losses. Hawaii's Department of Health maintains the regulations protect public safety by ensuring product testing and accurate labeling, while plaintiffs contend the state has effectively banned federally legal hemp products through impossible compliance standards. The lawsuit represents the latest flashpoint in ongoing tensions between state regulatory authority and federal hemp legalization, with potential implications for hemp markets nationwide.

Why This Matters

The Hawaii hemp restrictions affect an estimated 300-500 retail locations across the state, thousands of jobs, and a market valued at approximately $50-75 million annually in hemp-derived cannabinoid sales. For consumers, the enforcement means immediate loss of access to products many have used for pain management, anxiety relief, and sleep support. Hemp-derived cannabinoids like delta-8 THC and THCA have served as legal alternatives for individuals who cannot access Hawaii's medical cannabis program or prefer non-intoxicating CBD formulations with minor cannabinoids. Small business owners face existential threats. According to retailers quoted in court filings, the restrictions would force removal of 80-90 percent of current inventory, representing hundreds of thousands of dollars in unsellable product. Many operators invested significant capital in leases, buildouts, and inventory based on the legal framework established by the 2018 Farm Bill, only to face retroactive state prohibitions. The hemp manufacturing sector confronts supply chain disruption. Hawaii-based processors who extract and formulate hemp products for local and mainland distribution must either cease operations or relocate to states with more permissive frameworks. This affects upstream agricultural producers in states like Oregon, Colorado, and Kentucky who supply raw hemp biomass to Hawaiian processors. Legal precedent hangs in the balance. Federal courts have issued conflicting rulings on whether states can restrict hemp products that comply with the 2018 Farm Bill's definition of hemp as cannabis containing no more than 0.3 percent delta-9 THC by dry weight. A decision favoring Hawaii would embolden other states to impose similar restrictions; a ruling for plaintiffs would reinforce federal preemption of state hemp bans. Interstate commerce implications extend beyond Hawaii. If states can effectively prohibit federally legal hemp through testing requirements, potency limits on non-delta-9 cannabinoids, or registration schemes, the national hemp market fragments into a patchwork of incompatible state regimes, undermining the 2018 Farm Bill's intent to create a unified legal framework.

Background and History

The 2018 Farm Bill and Federal Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act and defined hemp as cannabis containing no more than 0.3 percent delta-9 THC on a dry weight basis. This federal legalization, championed by Senate Majority Leader Mitch McConnell, explicitly preserved state authority to regulate hemp production and sales within state borders but established hemp as a federally legal agricultural commodity. The 2018 Farm Bill directed the U.S. Department of Agriculture to establish a regulatory framework for hemp cultivation, which USDA published as the Final Rule on January 19, 2021. The law transferred hemp oversight from the Drug Enforcement Administration to USDA and removed hemp-derived products from FDA's drug scheduling authority, though FDA retained jurisdiction over hemp in food, beverages, and dietary supplements. Critically, the 2018 Farm Bill's definition focused exclusively on delta-9 THC concentration, making no mention of other cannabinoids like delta-8 THC, delta-10 THC, THC-O, or THCA. This omission created a legal gray area that entrepreneurs rapidly exploited, developing products containing intoxicating cannabinoids derived from legal hemp that fell outside the 0.3 percent delta-9 THC threshold.

Hawaii's Initial Hemp Framework (2019-2024)

Hawaii established its hemp pilot program in 2016 under the 2014 Farm Bill, then updated its framework following the 2018 Farm Bill to allow broader hemp cultivation and product sales. Act 228, signed into law on July 9, 2019, aligned Hawaii's hemp definition with federal law and authorized the Hawaii Department of Agriculture to regulate hemp farming. From 2019 through 2024, Hawaii's hemp market expanded rapidly with minimal state oversight. Retailers opened shops selling CBD tinctures, delta-8 THC vapes, THCA flower, and other hemp-derived products across Oahu, Maui, the Big Island, and Kauai. The market operated in a largely unregulated environment, with no mandatory testing, potency limits, or labeling requirements beyond basic federal guidelines. Hawaii's medical cannabis program, established in 2000 and expanded in 2015 to allow dispensaries, operated in parallel but remained restrictive. As of 2024, Hawaii had only eight licensed medical cannabis dispensaries statewide, serving approximately 35,000 registered patients. The limited access and high prices in the regulated medical market—often $50-70 per eighth of flower—drove consumers toward cheaper, more accessible hemp alternatives.

The 2025 Legislative Session and Act 55

Hawaii's legislature passed Act 55 during the 2025 session, signed into law by Governor Josh Green on June 15, 2025, imposing comprehensive restrictions on hemp-derived cannabinoid products with a one-year implementation timeline. Act 55 established several key requirements: Testing mandates requiring all hemp products to undergo analysis by ISO/IEC 17025-accredited laboratories for cannabinoid potency, heavy metals, pesticides, microbials, and residual solvents. Products must display certificates of analysis with batch-specific results. Potency limits capping total THC content (defined as delta-9 THC plus 0.877 times THCA) at 0.3 percent, effectively prohibiting high-THCA hemp flower that converts to delta-9 THC when heated. Labeling requirements mandating specific health warnings, cannabinoid content declarations, serving size information, and QR codes linking to full test results. Registration and permitting requiring all hemp retailers, manufacturers, and distributors to register with the Hawaii Department of Health and pay annual fees ranging from $1,000 to $5,000 depending on business type. Age restrictions prohibiting sales to individuals under 21 years old and requiring age verification for all transactions. The legislation passed with bipartisan support amid concerns about youth access to intoxicating hemp products and lack of quality control in the unregulated market. Proponents cited reports of emergency room visits related to delta-8 THC consumption and products failing independent testing for contaminants.

Implementation Delays and Industry Response

The Hawaii Department of Health initially planned to begin enforcement on July 1, 2025, but delayed implementation twice—first to January 1, 2026, then to July 1, 2026—citing the need to finalize regulations and establish the registration system. During the implementation period, hemp industry stakeholders organized opposition. The Hawaii Hemp Industry Association formed in late 2025 to advocate for amendments to Act 55. Retailers requested grandfather provisions for existing inventory, extended compliance timelines, and revised potency limits that would allow THCA flower and delta-8 products to remain legal. The Department of Health held public hearings in November 2025 and March 2026, receiving over 400 written comments, with approximately 85 percent opposing the restrictions as written. Commenters included business owners, consumers using hemp products for medical purposes, and mainland hemp manufacturers who supply Hawaiian retailers. Despite industry pressure, the Department of Health proceeded with enforcement plans. On June 1, 2026, the department published final administrative rules implementing Act 55 with minimal changes from the statutory language. Officials announced that beginning July 1, 2026, inspectors would visit hemp retailers statewide to verify compliance, with non-compliant products subject to seizure and businesses facing fines up to $10,000 per violation.

The Federal Lawsuit

On June 28, 2026, a coalition of hemp retailers, manufacturers, and industry associations filed a complaint in the U.S. District Court for the District of Hawaii seeking injunctive relief against enforcement of Act 55. Plaintiffs include approximately 15 named businesses operating in Hawaii, plus the Hawaii Hemp Industry Association representing over 100 member companies. The complaint names as defendants the Director of the Hawaii Department of Health, the Attorney General of Hawaii, and the Governor of Hawaii in their official capacities. The lawsuit advances three primary legal theories: Federal preemption under the Supremacy Clause, arguing that Act 55 conflicts with the 2018 Farm Bill by prohibiting hemp products that meet the federal definition of legal hemp containing no more than 0.3 percent delta-9 THC. Dormant Commerce Clause violations, contending that Hawaii's restrictions discriminate against interstate commerce by effectively banning hemp products manufactured in other states that comply with federal law. Void for vagueness under the Due Process Clause, asserting that Act 55's definitions and requirements are insufficiently clear to provide fair notice of prohibited conduct. Plaintiffs seek a preliminary injunction blocking enforcement of Act 55 pending resolution of the case, a declaratory judgment that the law violates federal law and the U.S. Constitution, and a permanent injunction against enforcement.

Key Players

Hawaii Department of Health

The Hawaii Department of Health serves as the primary regulatory agency responsible for implementing and enforcing Act 55's hemp product restrictions. The department's Cannabis Control Branch, established to oversee both medical cannabis and hemp regulation, developed the administrative rules translating Act 55's statutory requirements into specific compliance standards. Department officials have defended the restrictions as necessary consumer protection measures. In public statements, the department cited concerns about product mislabeling, contamination with heavy metals and pesticides, and youth access to intoxicating hemp products marketed with candy-like packaging and flavors. The department established a registration portal for hemp businesses in May 2026 but reported that fewer than 20 percent of estimated hemp retailers had completed registration by the July 1 enforcement deadline.

Hawaii Legislature

The Hawaii State Legislature initiated the hemp restrictions through Act 55, with key sponsorship from Senator Joy San Buenaventura and Representative Della Au Belatti. Supporters characterized the legislation as closing loopholes in the 2018 Farm Bill that allowed intoxicating products to be sold without the oversight applied to regulated cannabis. Legislative testimony during the 2025 session included input from the Hawaii Medical Association, which supported restrictions based on concerns about unregulated cannabinoid products, and law enforcement agencies that reported difficulty distinguishing legal hemp from illegal cannabis.

Hawaii Hemp Industry Association

The Hawaii Hemp Industry Association formed in 2025 as a trade group representing hemp retailers, manufacturers, and service providers operating in the state. The association serves as lead plaintiff in the federal lawsuit and has coordinated industry advocacy efforts including petition campaigns, legislative testimony, and public education initiatives. The association argues that Act 55 effectively bans federally legal hemp products through impossible compliance requirements, particularly the total THC calculation that includes THCA, and that the restrictions will eliminate hundreds of small businesses while driving consumers to unregulated black markets.

Individual Retailers and Manufacturers

Named plaintiffs in the lawsuit include hemp shops operating across Hawaii's major islands, representing businesses ranging from single-location retailers to small chains with multiple storefronts. Several plaintiffs are Native Hawaiian-owned businesses that invested in hemp retail as economic development opportunities in communities with limited employment options. Retailers report that products subject to removal under Act 55 include delta-8 THC vapes and edibles, THCA flower, delta-10 THC products, and CBD formulations containing minor cannabinoids above trace levels. One plaintiff stated in court filings that compliant inventory would reduce available products from approximately 200 SKUs to fewer than 20, consisting primarily of CBD isolate tinctures and topicals.

Mainland Hemp Manufacturers

Several mainland hemp companies joined the lawsuit as plaintiffs, including manufacturers based in Colorado, Oregon, and North Carolina that supply products to Hawaiian retailers. These companies argue that Hawaii's restrictions violate the dormant Commerce Clause by discriminating against interstate commerce in federally legal hemp products. Mainland manufacturers face significant financial harm from Hawaii's enforcement, as retailers return or refuse to purchase inventory that cannot be legally sold. Some companies report that Hawaii represented 5-10 percent of their total sales volume, making the market loss material to their operations.

Consumer Advocates and Medical Cannabis Patients

Consumer groups have split on Act 55, with some supporting restrictions as consumer protection and others opposing them as limiting access to beneficial products. The Drug Policy Forum of Hawaii, a reform advocacy organization, filed an amicus brief supporting plaintiffs and arguing that hemp restrictions push consumers toward more dangerous unregulated markets. Medical cannabis patients who use hemp products due to cost or access barriers have testified about the impact of restrictions. Some patients report that THCA flower provides similar therapeutic benefits to medical cannabis at one-third the price, making it essential for individuals on fixed incomes.

Legal and Regulatory Framework

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition explicitly includes "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" derived from compliant hemp, which industry advocates argue encompasses delta-8 THC, delta-10 THC, THCA, and other cannabinoids as long as delta-9 THC remains below 0.3 percent. The 2018 Farm Bill preserved state authority to regulate hemp within state borders through Section 10114, which states: "Nothing in this section prohibits the production of hemp in a State or the territory of an Indian tribe that allows the production of hemp under the law of the State or territory of the Indian tribe." Courts have interpreted this provision differently, with some finding it allows states to ban hemp entirely, while others conclude it permits regulation of production but not prohibition of federally legal products in commerce.

DEA Interim Final Rule on Hemp

The Drug Enforcement Administration published an Interim Final Rule on August 21, 2020, implementing the 2018 Farm Bill's hemp provisions and confirming that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The DEA rule, codified at 21 CFR § 1308.35, created controversy by stating that "for synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance." This language raised questions about the legal status of delta-8 THC and other cannabinoids produced through chemical conversion of CBD, even when derived from legal hemp. The DEA has not taken enforcement action against hemp-derived cannabinoid products, leaving regulatory uncertainty that states have attempted to resolve through their own restrictions.

FDA Position on Hemp in Food and Supplements

The Food and Drug Administration maintains that CBD and other cannabinoids cannot be lawfully added to food or marketed as dietary supplements under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. FDA's position stems from the fact that CBD was the active ingredient in the approved drug Epidiolex before being marketed in food or supplements, triggering the drug exclusion rule under 21 U.S.C. § 321(ff)(3)(B). However, FDA has exercised enforcement discretion, issuing warning letters to companies making egregious health claims but generally not pursuing enforcement against hemp CBD products. This regulatory gap has allowed the hemp market to flourish despite technical illegality under FDA rules, with states stepping in to fill the oversight void through their own testing and labeling requirements.

Hawaii Act 55 Statutory Provisions

Hawaii Revised Statutes § 329D-2, as amended by Act 55, establishes comprehensive requirements for hemp-derived cannabinoid products sold in Hawaii. Key statutory provisions include: Testing requirements under § 329D-8 mandating analysis by ISO/IEC 17025-accredited laboratories for potency, contaminants, and adulterants, with specific action levels for heavy metals (lead, arsenic, cadmium, mercury), pesticides, microbials (E. coli, Salmonella, Aspergillus), and residual solvents. Total THC calculation under § 329D-2 defining total THC as "delta-9 THC plus 0.877 times THCA," effectively limiting THCA content to trace levels since the conversion factor accounts for THCA's molecular weight difference from delta-9 THC. Labeling mandates under § 329D-9 requiring health warnings, cannabinoid content declarations, serving size information, batch numbers, and QR codes linking to certificates of analysis. Registration requirements under § 329D-5 requiring all hemp retailers, manufacturers, and distributors to register with the Department of Health and renew annually, with fees ranging from $1,000 for small retailers to $5,000 for manufacturers. Penalties under § 329D-12 authorizing fines up to $10,000 per violation, product seizure, and license revocation for non-compliance.

Constitutional Challenges

The federal lawsuit challenges Act 55 under three constitutional theories: federal preemption, the dormant Commerce Clause, and void for vagueness. The preemption argument relies on the Supremacy Clause, U.S. Const. art. VI, cl. 2, which establishes federal law as supreme over conflicting state law. Plaintiffs argue that Act 55 conflicts with the 2018 Farm Bill by prohibiting hemp products that meet the federal definition of legal hemp, creating an obstacle to Congress's purpose of establishing a national hemp market. Hawaii will likely defend by citing the 2018 Farm Bill's savings clause preserving state regulatory authority and arguing that Act 55 regulates rather than prohibits hemp, imposing quality control measures within the state's police power. The dormant Commerce Clause claim, based on the principle that states cannot discriminate against interstate commerce even absent federal legislation, argues that Act 55 effectively excludes hemp products manufactured in other states that comply with federal law. Plaintiffs cite Pike v. Bruce Church, Inc., 397 U.S. 137 (1970), which requires state regulations affecting interstate commerce to serve legitimate local interests without imposing excessive burdens on interstate trade. The void for vagueness challenge contends that Act 55's definitions fail to provide fair notice of prohibited conduct, particularly regarding which cannabinoids are restricted and how the total THC calculation applies to various product types.

State-by-State Breakdown of Hemp Restrictions

At least 18 states have enacted restrictions on hemp-derived cannabinoid products beyond the 2018 Farm Bill's 0.3 percent delta-9 THC limit, creating a fragmented regulatory landscape.

States with Comprehensive Hemp Cannabinoid Bans

Alaska, Colorado, Delaware, Montana, New York, Oregon, Rhode Island, and Vermont have banned or severely restricted delta-8 THC and similar hemp-derived intoxicating cannabinoids. Colorado's approach is particularly notable given its status as a major hemp producer. The state's Marijuana Enforcement Division issued guidance in 2021 classifying delta-8 THC as a Schedule I controlled substance under state law, regardless of its hemp origin. Colorado allows delta-8 THC sales only through licensed marijuana dispensaries subject to the state's 15 percent excise tax and 15 percent retail tax. New York's Office of Cannabis Management banned delta-8 THC and other intoxicating hemp cannabinoids in 2022, limiting legal hemp products to those containing CBD and non-intoxicating cannabinoids. The state requires all hemp products to undergo testing and registration, with enforcement beginning in 2023. Oregon's Liquor and Cannabis Commission adopted rules in 2021 prohibiting artificially derived cannabinoids, including delta-8 THC produced through chemical conversion of CBD. The state allows naturally occurring cannabinoids in hemp but requires testing to verify they were not synthetically created.

States with Testing and Labeling Requirements

California, Florida, Louisiana, Michigan, Minnesota, Nevada, and Washington have implemented testing, labeling, and registration requirements for hemp products without banning specific cannabinoids. California's AB 45, signed in October 2023, established comprehensive hemp regulations requiring testing by licensed laboratories, child-resistant packaging, and serving size limits of 10 mg of total THC per package. The law allows hemp-derived cannabinoids including delta-8 THC and THCA but subjects them to the same testing standards as cannabis products. Florida's Department of Agriculture and Consumer Services issued rules in 2022 requiring hemp products to display certificates of analysis and prohibiting health claims. The state has not banned delta-8 THC but requires products to comply with the 0.3 percent delta-9 THC limit. Michigan's Marijuana Regulatory Agency published guidance in 2021 allowing delta-8 THC and other hemp cannabinoids but requiring products to undergo testing for potency and contaminants. The state treats hemp-derived cannabinoids as distinct from marijuana, allowing sales outside the licensed cannabis system.

States with Minimal Hemp Regulation

Alabama, Georgia, Indiana, Kentucky, Missouri, North Carolina, South Carolina, Tennessee, Texas, and Wisconsin maintain minimal restrictions on hemp products beyond federal requirements. These states generally allow delta-8 THC, THCA flower, and other hemp-derived cannabinoids as long as products comply with the 0.3 percent delta-9 THC limit. Some states have issued guidance clarifying that hemp-derived cannabinoids are legal, while others have simply not addressed the issue, allowing markets to develop without state oversight. Texas represents a significant market, with thousands of hemp retailers operating across the state. The Texas Department of State Health Services has not restricted hemp-derived cannabinoids, and legislative attempts to ban delta-8 THC have failed in multiple sessions.

States with Pending Legislation

Arizona, Illinois, Maryland, Massachusetts, New Jersey, and Virginia have pending legislation or regulatory proceedings addressing hemp-derived cannabinoids. Illinois introduced HB 4161 in 2024 to regulate hemp-derived cannabinoids through the state's cannabis licensing system, requiring testing and limiting sales to licensed dispensaries. The bill remains in committee as of mid-2026. Massachusetts' Cannabis Control Commission opened a public comment period in 2025 on proposed regulations for hemp-derived cannabinoids, considering options ranging from outright bans to integration into the licensed cannabis market.

Market and Business Implications

Hawaii Market Size and Structure

Hawaii's hemp-derived cannabinoid market generated an estimated $50-75 million in annual sales as of 2025, supporting 300-500 retail locations and approximately 1,500-2,000 jobs across the islands. The market structure consists primarily of small, independent retailers operating single-location shops, with a handful of small chains operating 3-5 locations. Retail formats include dedicated hemp and CBD stores, vape shops that added hemp products, and convenience stores carrying a limited selection of hemp items. Product mix varies by retailer, but industry surveys suggest that delta-8 THC products accounted for approximately 40-50 percent of sales, THCA flower represented 20-30 percent, CBD products comprised 15-20 percent, and other cannabinoids (delta-10, HHC, THC-O) made up the remainder. Average retail prices for hemp products in Hawaii run higher than mainland markets due to shipping costs and limited competition. Delta-8 THC vape cartridges typically retail for $35-50, THCA flower sells for $30-40 per eighth, and CBD tinctures range from $40-80 depending on potency.

Impact on Retailers

Retailers face inventory losses ranging from $50,000 to $300,000 per location, depending on store size and product mix, as non-compliant products must be removed from shelves. Small retailers with limited capital reserves may be unable to absorb these losses and continue operations. Several retailers quoted in media reports indicated they would likely close rather than attempt to operate with the drastically reduced product selection allowed under Act 55. Retailers that attempt to continue operations face the challenge of sourcing compliant products. Few manufacturers currently produce hemp products meeting Hawaii's total THC calculation, as the 0.877 conversion factor for THCA effectively limits total cannabinoid content to levels that many consumers find insufficiently potent. Lease obligations present additional financial pressure. Many retailers signed multi-year commercial leases based on revenue projections that assumed continued legality of their product mix. Breaking leases early or continuing to pay rent while operating unprofitable businesses will force difficult decisions.

Impact on Manufacturers and Distributors

Hemp manufacturers supplying Hawaiian retailers face immediate revenue loss and potential inventory write-offs for products that can no longer be sold in the state. Mainland manufacturers report that Hawaiian retailers have cancelled orders and returned inventory in anticipation of the July 1 enforcement date. Some manufacturers have offered to accept returns and provide credits, absorbing the loss themselves, while others have enforced no-return policies, leaving retailers holding unsellable inventory. Manufacturers must decide whether to reformulate products to meet Hawaii's requirements, which would require significant research and development investment for a relatively small market, or to exit the Hawaii market entirely and focus on states with more permissive regulations. Hawaii-based processors and manufacturers face the choice of relocating operations to other states or pivoting to compliant products. Relocation involves significant costs for moving equipment, establishing new facilities, and obtaining licenses in other jurisdictions. Pivoting to compliant products may not be economically viable if consumer demand proves insufficient.

Multi-State Operator (MSO) Implications

Hawaii's restrictions may benefit licensed cannabis MSOs by reducing competition from hemp products, though the small size of Hawaii's market limits the impact on major operators. Hawaii's licensed medical cannabis market operates through eight dispensary licenses, each allowing two production facilities and two retail locations. License holders include Aloha Green Holdings, Cure Oahu, Green Aloha Ltd., Manoa Botanicals, Maui Grown Therapies, Noa Botanicals, Pono Life Sciences Maui, and Big Island Grown. These operators have advocated for hemp restrictions, arguing that unregulated hemp products undercut their heavily regulated and taxed businesses. With hemp competition reduced, licensed dispensaries may capture some customers who previously purchased hemp products, though high prices and limited product selection in the medical program may drive others to cease use or turn to illicit markets. Major mainland MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs do not operate in Hawaii due to the state's limited market size and restrictive licensing structure. Hawaii's actions may nonetheless influence these operators' strategies in other states where they face hemp competition.

Investment and Capital Markets

Hawaii's enforcement adds to growing regulatory uncertainty in the hemp sector, complicating capital raising and valuation for hemp companies. Venture capital and private equity investors have largely retreated from the hemp-derived cannabinoid sector over the past two years as regulatory risks have increased. The patchwork of state restrictions makes it difficult to build scalable national brands, and the threat of federal enforcement under the DEA's synthetic cannabinoid rules creates existential risk. Public hemp companies have seen valuations decline significantly. Several companies that went public through SPAC mergers in 2021-2022 have seen share prices fall 70-90 percent as revenue growth has stalled amid regulatory headwinds. Debt financing has become scarce for hemp operators. Banks remain hesitant to provide services to hemp businesses due to regulatory uncertainty, and alternative lenders charge interest rates of 15-25 percent, making growth capital prohibitively expensive.

Consumer Behavior and Market Shifts

Consumer responses to hemp restrictions typically follow one of four patterns: switching to licensed cannabis, purchasing compliant hemp products, buying from illicit markets, or ceasing use entirely. In states that have banned delta-8 THC and similar products, surveys suggest approximately 30-40 percent of former hemp consumers switched to licensed cannabis where available, 20-30 percent continued purchasing hemp products online or from illicit sources, 15-25 percent switched to compliant CBD products, and 15-25 percent stopped using cannabinoid products. Hawaii's unique geography complicates these patterns. As an island state, illicit market access is more limited than in mainland states where consumers can easily cross borders. Online purchases remain an option, though enforcement of Act 55 may include provisions targeting online sales and delivery. Price sensitivity will drive many decisions. Licensed medical cannabis in Hawaii costs 2-3 times more than hemp products for comparable potency, making the switch unaffordable for many consumers. This may push more users toward illicit markets or cessation than in states with more affordable legal cannabis.

What Experts Say

Legal scholars, industry analysts, and policy experts have offered varied perspectives on Hawaii's hemp restrictions and the broader trend of state-level regulation. Cannabis law attorneys have noted that federal courts have reached inconsistent conclusions on whether the 2018 Farm Bill preempts state hemp bans. According to analysis from Vicente Sederberg LLP, a leading cannabis law firm, the Fifth Circuit's decision in Hometown Hero CBD v. Texas DSHS (2023) found that Texas could not ban delta-8 THC because it conflicted with federal hemp law, while the Eighth Circuit in Minnesota Hemp Farms v. Ellison (2024) upheld Minnesota's authority to restrict hemp products under the state's police powers. Policy experts at the RAND Corporation have published research suggesting that unregulated hemp-derived cannabinoid markets pose public health risks due to inconsistent product quality, contamination, and lack of age verification. According to RAND's analysis, state testing and labeling requirements serve legitimate consumer protection interests, though outright bans may be counterproductive by pushing consumers to unregulated sources. Industry economists have projected that state-by-state hemp restrictions could reduce the national hemp-derived cannabinoid market by 30-50 percent over the next three years, from approximately $2.8 billion in 2025 to $1.5-2 billion by 2028. This contraction would primarily affect small and mid-sized hemp companies, with capital flowing instead to licensed cannabis operators in states with adult-use programs. Public health researchers at Johns Hopkins University have called for federal action to establish national standards for hemp products, arguing that the current patchwork of state regulations creates consumer confusion and undermines public health goals. According to Johns Hopkins analysis, federal legislation establishing testing requirements, potency limits, and age restrictions would be more effective than state-by-state approaches. Consumer advocates have emphasized the importance of maintaining access to hemp products for individuals who use them for wellness purposes. According to the Hemp Roundtable, an industry trade association, surveys indicate that approximately 60 percent of hemp product consumers use them to address specific health concerns including pain, anxiety, and sleep issues, with many reporting that hemp products are more affordable and accessible than alternatives.

What's Next

The Hawaii hemp restrictions lawsuit will proceed through federal court with several key decision points over the next 6-12 months. The immediate next step is a hearing on plaintiffs' motion for a preliminary injunction, likely to be scheduled within 30-60 days of filing. At this hearing, U.S. District Judge Derrick Watson or another judge in the District of Hawaii will consider whether plaintiffs have demonstrated a likelihood of success on the merits, irreparable harm, balance of equities favoring an injunction, and that an injunction serves the public interest. If the court grants a preliminary injunction, enforcement of Act 55 would be stayed pending resolution of the case, allowing hemp retailers to continue operating with their current product mix. If the court denies the injunction, enforcement would proceed, forcing retailers to remove non-compliant products while the case continues. Discovery would follow the preliminary injunction decision, with both sides gathering evidence through document requests, depositions, and expert reports. This phase typically takes 6-9 months in federal court. Summary judgment motions would likely be filed after discovery closes, with both sides arguing that no material facts are in dispute and that they are entitled to judgment as a matter of law. The court's decision on summary judgment could resolve the case without trial. If the case proceeds to trial, a decision would likely come in late 2027 or early 2028. Either side could appeal to the Ninth Circuit Court of Appeals, potentially extending the litigation another 12-18 months. Parallel to the litigation, legislative solutions remain possible. The Hawaii Legislature could amend Act 55 during the 2027 session to address industry concerns,